<code id='CCD84CC5DD'></code><style id='CCD84CC5DD'></style>
    • <acronym id='CCD84CC5DD'></acronym>
      <center id='CCD84CC5DD'><center id='CCD84CC5DD'><tfoot id='CCD84CC5DD'></tfoot></center><abbr id='CCD84CC5DD'><dir id='CCD84CC5DD'><tfoot id='CCD84CC5DD'></tfoot><noframes id='CCD84CC5DD'>

    • <optgroup id='CCD84CC5DD'><strike id='CCD84CC5DD'><sup id='CCD84CC5DD'></sup></strike><code id='CCD84CC5DD'></code></optgroup>
        1. <b id='CCD84CC5DD'><label id='CCD84CC5DD'><select id='CCD84CC5DD'><dt id='CCD84CC5DD'><span id='CCD84CC5DD'></span></dt></select></label></b><u id='CCD84CC5DD'></u>
          <i id='CCD84CC5DD'><strike id='CCD84CC5DD'><tt id='CCD84CC5DD'><pre id='CCD84CC5DD'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:18852
          Peter Marks. -- health coverage from STAT
          Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

          Peter Marks wants drug developers to ask more stupid questions.

          It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data. 

          advertisement

          The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          NIH confirmation hearing shows politicization of research
          NIH confirmation hearing shows politicization of research

          MonicaBertagnolli,thenomineetoleadtheNationalInstitutesofHealthJeffChiu/APMonicaBertagnolli,Presiden

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Impact of Dobbs ruling felt at reproductive medicine meeting

          MathieuLewis-Rolland/GettyImagesNEWORLEANS—TheannualmeetingoftheAmericanSocietyofReproductiveMedicin